RecoveryLow Risk
Larazotide
Also known as: AT1001, Larazotide acetate
- Half-life:
- ~30 minutes (local gut action)
Administration Routes
oral
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.
Mechanism of Action
Synthetic octapeptide that prevents zonulin-mediated tight junction opening; maintains intestinal epithelial barrier integrity
A gut-targeted peptide that restores intestinal tight junctions disrupted by zonulin. Particularly studied for celiac disease and leaky gut syndrome.
Primary Research Areas
- tight junction restoration
- intestinal barrier repair
- leaky gut prevention
Risk Profile
Low Risk
Generally considered lower risk in research contexts. Consult a healthcare professional before use.
Regulatory Status
Research OnlyInvestigational
Tight junction regulator (AT-1001) for celiac disease. Phase 3 ILIT-1 (NCT02633956) failed primary endpoint 2019. No NDA filed. Additional Phase 3 planned by ImmunoGenX. Investigational.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.